GPR84

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Probable G-protein coupled receptor 84 is a protein that in humans is encoded by the GPR84 gene.

Probable G-protein coupled receptor 84 is a protein that in humans is encoded by the GPR84 gene.

Agonists

The ligands for GPR84 suggest also a relationship between inflammation and fatty acid sensing or regulation. Medium-chain free fatty acids (FFA) with carbon chain lengths of C9 to C14. Capric acid (C10:0), undecanoic acid (C11:0), and lauric acid (C12:0) are the most potent described endogenous agonists of GPR84. Not activated by short-chain and long-chain saturated and unsaturated FFAs induced in monocytes or macrophages by lipopolysaccharide (LPS). In addition, the activation of GPR84 in monocytes/macrophages amplifies LPS stimulated interleukin-12 (IL-12) p40 production in a concentration-dependent manner. IL-12 plays an important role in promoting cell-mediated immunity to eradicate pathogens by inducing and maintaining T helper 1 responses and inhibiting T helper 2 responses. Medium-chain FFAs inhibited forskolin-induced cAMP production and stimulated [35S]GTPgammaS binding in a GPR84-dependent manner. The values for medium-chain FFAs capric acid, undecanoic acid, and lauric acid at GPR84 (4, 8, and 9 mM, respectively, in the cAMP assay). These results suggest that GPR84 activation by medium-chain FFAs is coupled to a pertussis toxin-sensitive Gi/o pathway. Besides medium-chain FFAs, diindolylmethane was also described as GPR84 agonist. However, the target selectivity of this molecule is also questionable because diindolylmethane is an aryl hydrocarbon receptor modulator, too. The patent literature mentions that besides medium-chain FFAs other substances as embelin (2,5-dihydroxy-3-undecyl(1,4)benzoquinone), icosa-5,8,11,14-tetraynoic acid, and 5S,6R-dihydroxy-icosa-7,9,11,14-tetraenoic acid (5S,6RdiHETE) are also ligands of GPR84. These two latest molecules say against the statement that long-chain FFAs are not ligands of GPR84. Based on these results it is probable that besides medium-chain FFAs some long chain FFAs can also be endogenous ligands of GPR84. Further work is needed to confirm this hypothesis.

Antagonists

The molecule GLPG1205, a selective GPR84 antagonist, was under investigation by the Belgian firm Galapagos NV. Its clinical effect against inflammatory disorders like inflammatory bowel disease was being investigated in 2015 in a Phase 2 Proof-of-Concept study in ulcerative colitis patients. The results published in January 20161 showed good pharmacokinetics, safety and tolerability. However, the target efficacy was not met. The development of GLPG1205 for ulcerative colitis was therefore stopped. Fezagepras (setogepram; PBI-4050), which is a FFAR1 (GPR40) agonist and GPR84 antagonist, was under investigation by the Canadian biotechnology firm Prometic for the treatment of fibrosis, but was discontinued in 2022. LMNL-6511 is a selective GPR84 antagonist which is in phase 1/2 clinical trials for treatment of fibrosis.

Classification of GPR84

Based on its binding and activation by medium-chain fatty acids, GPR84 has been recognized as a possible member of the free fatty acid receptor family. However, GPR84 has not yet been given a FFAR designation possibly because capric acid, the most potent medium-chain fatty acid in activating GPR44, requires high concentrations (e.g., in the micromolar range) to do so. This consideration supports the need to search for other naturally occurring agents that are more potent than caproic acid in activating this receptor. In the meantime, GPR84 continues to be defined as an orphan receptor, i.e., a receptor whose naturally occurring activator(s) is unclear.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377968821 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia publication date (×1) · confidence 0.95 https://en.wikipedia.org/w/index.php?oldid=1377968821

Sources cited in this revision

Extracted from the cited revision's reference blocks; absent citations are not invented.